Article ; Online: Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.
Drug metabolism and disposition: the biological fate of chemicals
2023 Volume 51, Issue 6, Page(s) 685–699
Abstract: The development of safe and effective medications requires a profound understanding of their pharmacokinetic (PK) and pharmacodynamic properties. PK studies have been built through investigation of enzymes and transporters that drive drug absorption, ... ...
| Abstract | The development of safe and effective medications requires a profound understanding of their pharmacokinetic (PK) and pharmacodynamic properties. PK studies have been built through investigation of enzymes and transporters that drive drug absorption, distribution, metabolism, and excretion (ADME). Like many other disciplines, the study of ADME gene products and their functions has been revolutionized through the invention and widespread adoption of recombinant DNA technologies. Recombinant DNA technologies use expression vectors such as plasmids to achieve heterologous expression of a desired transgene in a specified host organism. This has enabled the purification of recombinant ADME gene products for functional and structural characterization, allowing investigators to elucidate their roles in drug metabolism and disposition. This strategy has also been used to offer recombinant or bioengineered RNA (BioRNA) agents to investigate the posttranscriptional regulation of ADME genes. Conventional research with small noncoding RNAs such as microRNAs (miRNAs) and small interfering RNAs has been dependent on synthetic RNA analogs that are known to carry a range of chemical modifications expected to improve stability and PK properties. Indeed, a novel transfer RNA fused pre-miRNA carrier-based bioengineering platform technology has been established to offer consistent and high-yield production of unparalleled BioRNA molecules from |
|---|---|
| MeSH term(s) | DNA, Recombinant ; MicroRNAs/genetics ; RNA, Small Interfering/genetics ; Metabolic Clearance Rate ; Technology ; Recombinant Proteins ; Pharmacokinetics |
| Chemical Substances | DNA, Recombinant ; MicroRNAs ; RNA, Small Interfering ; Recombinant Proteins |
| Language | English |
| Publishing date | 2023-03-22 |
| Publishing country | United States |
| Document type | Journal Article ; Review ; Research Support, N.I.H., Extramural |
| ZDB-ID | 186795-7 |
| ISSN | 1521-009X ; 0090-9556 |
| ISSN (online) | 1521-009X |
| ISSN | 0090-9556 |
| DOI | 10.1124/dmd.122.001008 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1014: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.